Evidence map›Paper›PMID 33708028›Full record

ArticleAdvanced functional materials2020

Injectable Drug-Releasing Microporous Annealed Particle Scaffolds for Treating Myocardial Infarction.

Jun Fang, Jaekyung Koh, Qizhi Fang, Huiliang Qiu, Maani M Archang, Mohammad Mahdi Hasani-Sadrabadi, Hiromi Miwa, Xintong Zhong, Richard Sievers, Dong-Wei Gao and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Granular Hydrogels for Harnessing the Immune Response.Advanced healthcare materials · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Jun FangDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA.
Jaekyung KohDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA.
Qizhi FangDepartment of Medicine, Cardiovascular Research Institute and Institute for Regeneration Medicine University of California, San Francisco, CA 94143, USA.
Huiliang QiuDepartment of Medicine, Cardiovascular Research Institute and Institute for Regeneration Medicine University of California, San Francisco, CA 94143, USA.
Maani M ArchangDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA.
Mohammad Mahdi Hasani-SadrabadiDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA.
Hiromi MiwaDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA.
Xintong ZhongDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA.
Richard SieversDepartment of Medicine, Cardiovascular Research Institute and Institute for Regeneration Medicine University of California, San Francisco, CA 94143, USA.
Dong-Wei GaoDepartment of Medicine, Cardiovascular Research Institute and Institute for Regeneration Medicine University of California, San Francisco, CA 94143, USA.
Randall LeeDepartment of Medicine, Cardiovascular Research Institute and Institute for Regeneration Medicine University of California, San Francisco, CA 94143, USA.
Dino Di CarloDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA.
Song LiDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USUniversity of California, San Francisco · USCalifornia NanoSystems Institute · US

Funding

UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
Regenerative Musculoskeletal Medicine Training ProgramT32AR059033 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI John S Adams, Nicholas M. Bernthal · 2011 to 2026
$4.8M
In Situ Regeneration of Blood VesselR01HL121450 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, SONG · 2015 to 2018
$1.8M
Dermatology Scientist Training ProgramT32AR071307 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MODLIN, ROBERT L · 2017 to 2021
$1.1M
NHLBI NIH HHS R01 HL121450NIAMS NIH HHS T32 AR059033NIAMS NIH HHS T32 AR071307NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

Intramyocardial injection of hydrogels offers great potential for treating myocardial infarction (MI) in a minimally invasive manner. However, traditional bulk hydrogels generally lack microporous structures to support rapid tissue ingrowth and biochemical signals to prevent fibrotic remodeling toward heart failure. To address such challenges, a novel drug-releasing microporous annealed particle (drugMAP) system is developed by encapsulating hydrophobic drug-loaded nanoparticles into microgel building blocks via microfluidic manufacturing. By modulating nanoparticle hydrophilicity and pregel solution viscosity, drugMAP building blocks are generated with consistent and homogeneous encapsulation of nanoparticles. In addition, the complementary effects of forskolin (F) and Repsox (R) on the functional modulations of cardiomyocytes, fibroblasts, and endothelial cells in vitro are demonstrated. After that, both hydrophobic drugs (F and R) are loaded into drugMAP to generate FR/drugMAP for MI therapy in a rat model. The intramyocardial injection of MAP gel improves left ventricular functions, which are further enhanced by FR/drugMAP treatment with increased angiogenesis and reduced fibrosis and inflammatory response. This drugMAP platform represents a new generation of microgel particles for MI therapy and will have broad applications in regenerative medicine and disease therapy.

Indexed as

drug deliverygranular hydrogelsmicrogelsmyocardial infarctiontissue engineering

Identifiers

PMID33708028
PMCPMC7942842
OpenAlexW3084436386

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.